Description: This session will focus on advancements in the diagnosis, treatment, and risk stratification of hypertrophic cardiomyopathy (HCM), particularly the obstructive form. A major theme is the real-world effectiveness and safety of mavacamten, a cardiac myosin inhibitor, both alone and in combination with standard therapies. Studies also explore genetic underpinnings of HCM (e.g., novel β-MYH7 mutations), the use of AI for diagnosis and risk prediction, and gender disparities in outcomes after septal ablation. This is not a CE accredited session.

Moderator:
Sakthivel Sadayappan (University of Arizona)